Publication: Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials
Issued Date
2012-08-01
Resource Type
ISSN
00221899
Other identifier(s)
2-s2.0-84863932778
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Infectious Diseases. Vol.206, No.3 (2012), 431-441
Suggested Citation
David C. Montefiori, Chitraporn Karnasuta, Ying Huang, Hasan Ahmed, Peter Gilbert, Mark S. De Souza, Robert McLinden, Sodsai Tovanabutra, Agnes Laurence-Chenine, Eric Sanders-Buell, M. Anthony Moody, Mattia Bonsignori, Christina Ochsenbauer, John Kappes, Haili Tang, Kelli Greene, Hongmei Gao, Celia C. Labranche, Charla Andrews, Victoria R. Polonis, Supachai Rerks-Ngarm, Punnee Pitisuttithum, Sorachai Nitayaphan, Jaranit Kaewkungwal, Steve G. Self, Phillip W. Berman, Donald Francis, Faruk Sinangil, Carter Lee, Jim Tartaglia, Merlin L. Robb, Barton F. Haynes, Nelson L. Michael, Jerome H. Kim Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. Journal of Infectious Diseases. Vol.206, No.3 (2012), 431-441. doi:10.1093/infdis/jis367 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/14719
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials
Author(s)
David C. Montefiori
Chitraporn Karnasuta
Ying Huang
Hasan Ahmed
Peter Gilbert
Mark S. De Souza
Robert McLinden
Sodsai Tovanabutra
Agnes Laurence-Chenine
Eric Sanders-Buell
M. Anthony Moody
Mattia Bonsignori
Christina Ochsenbauer
John Kappes
Haili Tang
Kelli Greene
Hongmei Gao
Celia C. Labranche
Charla Andrews
Victoria R. Polonis
Supachai Rerks-Ngarm
Punnee Pitisuttithum
Sorachai Nitayaphan
Jaranit Kaewkungwal
Steve G. Self
Phillip W. Berman
Donald Francis
Faruk Sinangil
Carter Lee
Jim Tartaglia
Merlin L. Robb
Barton F. Haynes
Nelson L. Michael
Jerome H. Kim
Chitraporn Karnasuta
Ying Huang
Hasan Ahmed
Peter Gilbert
Mark S. De Souza
Robert McLinden
Sodsai Tovanabutra
Agnes Laurence-Chenine
Eric Sanders-Buell
M. Anthony Moody
Mattia Bonsignori
Christina Ochsenbauer
John Kappes
Haili Tang
Kelli Greene
Hongmei Gao
Celia C. Labranche
Charla Andrews
Victoria R. Polonis
Supachai Rerks-Ngarm
Punnee Pitisuttithum
Sorachai Nitayaphan
Jaranit Kaewkungwal
Steve G. Self
Phillip W. Berman
Donald Francis
Faruk Sinangil
Carter Lee
Jim Tartaglia
Merlin L. Robb
Barton F. Haynes
Nelson L. Michael
Jerome H. Kim
Other Contributor(s)
Duke University School of Medicine
Armed Forces Research Institute of Medical Sciences, San Francisco
Fred Hutchinson Cancer Research Center
Walter Reed Army Institute of Research
University of Alabama
Ministry of Public Health
Mahidol University
University of California, Santa Cruz
Global Solutions for Infectious Diseases
Sanofi Pasteur
Armed Forces Research Institute of Medical Sciences, San Francisco
Fred Hutchinson Cancer Research Center
Walter Reed Army Institute of Research
University of Alabama
Ministry of Public Health
Mahidol University
University of California, Santa Cruz
Global Solutions for Infectious Diseases
Sanofi Pasteur
Abstract
Background. A recombinant canarypox vector expressing human immunodeficiency virus type 1 (HIV-1) Gag, Pro, and membrane-linked gp120 (vCP1521), combined with a bivalent gp120 protein boost (AIDSVAX B/E), provided modest protection against HIV-1 infection in a community-based population in Thailand (RV144 trial). No protection was observed in Thai injection drug users who received AIDSVAX B/E alone (Vax003 trial). We compared the neutralizing antibody response in these 2 trials. Methods. Neutralization was assessed with tier 1 and tier 2 strains of virus in TZM-bl and A3R5 cells. Results. Neutralization of several tier 1 viruses was detected in both RV144 and Vax003. Peak titers were higher in Vax003 and waned rapidly in both trials. The response in RV144 was targeted in part to V3 of gp120.vCP1521 priming plus 2 boosts with gp120 protein was superior to 2 gp120 protein inoculations alone, confirming a priming effect for vCP1521. Sporadic weak neutralization of tier 2 viruses was detected only in Vax003 and A3R5 cells.Conclusion.The results suggest either that weak neutralizing antibody responses can be partially protective against HIV-1 in low-risk heterosexual populations or that the modest efficacy seen in RV144 was mediated by other immune responses, either alone or in combination with neutralizing antibodies. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. © 2012 The Author.
